HRT Financial’s Roivant Sciences ROIV Stock Holding History

HRT Financial’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.2M	Buy	+2,463,000	New	+$72.8M	0.16%	100

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

HRT Financial's ROIV Position: Q1 2026 in Review

HRT Financial sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 219,191 shares — an estimated $4.76M sold.

HRT Financial first reported a position in ROIV in Q1 2022 and held it in 9 quarters. The position peaked at $7.36M in Q3 2025. 444 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

HRT Financial reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
HRT Financial sold 219,191 Roivant Sciences shares in Q1 2026, an estimated $4.76M.
HRT Financial first reported a position in Roivant Sciences in Q1 2022 and held it in 9 quarters.
HRT Financial's Roivant Sciences position peaked at $7.36M in Q3 2025.
444 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.